Genmark Diagnostics (GNMK) Stock Price & Overview
NASDAQ:GNMK
Current stock price
The current stock price of GNMK is 24.04 null. Today GNMK is down by 0%. In the past month the price increased by 0.21%. In the past year, price increased by 116.19%.
GNMK Key Statistics
- Market Cap
- 1.757B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.28
- Dividend Yield
- N/A
GNMK Stock Performance
GNMK Stock Chart
GNMK Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to GNMK. When comparing the yearly performance of all stocks, GNMK is one of the better performing stocks in the market, outperforming 87.03% of all stocks.
GNMK Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to GNMK. GNMK scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
GNMK Earnings
GNMK Forecast & Estimates
GNMK Financial Highlights
Over the last trailing twelve months GNMK reported a non-GAAP Earnings per Share(EPS) of -0.28. The EPS increased by 65.85% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -10.87% | ||
| ROA | -8.34% | ||
| ROE | N/A | ||
| Debt/Equity | 0.76 |
GNMK Ownership
About GNMK
Company Profile
GenMark Diagnostics, Inc. is a molecular diagnostics company focused on developing and commercializing its proprietary eSensor(R) detection technology. The eSensor' XT-8 system is the second generation in GenMark Dx's eSensor' platform, utilizing electrochemical detection technology to detect nucleic acids on a microarray. The XT-8 System enables multiplex detection of DNA and RNA targets. The Company has developed four diagnostic tests for use with its XT-8 System. Its Cystic Fibrosis Genotyping Test, which detects pre-conception risks of cystic fibrosis, and its Warfarin Sensitivity Test, which determines an individual's ability to metabolize the oral anticoagulant warfarin, have received FDA clearance. It has also developed a Respiratory Viral Panel Test, which detects the presence of major respiratory viruses, and a Thrombosis Risk Test, which detects an individual's increased risk of blood clots. GenMark Diagnostics, Inc. is based in Pasadena, California.
Company Info
Genmark Diagnostics
5964 LA PLACE COURT
CARLSBAD CA 92008
CEO: Scott Mendel
Phone: 760-448-4300
Genmark Diagnostics / GNMK FAQ
Can you describe the business of Genmark Diagnostics?
GenMark Diagnostics, Inc. is a molecular diagnostics company focused on developing and commercializing its proprietary eSensor(R) detection technology. The eSensor' XT-8 system is the second generation in GenMark Dx's eSensor' platform, utilizing electrochemical detection technology to detect nucleic acids on a microarray. The XT-8 System enables multiplex detection of DNA and RNA targets. The Company has developed four diagnostic tests for use with its XT-8 System. Its Cystic Fibrosis Genotyping Test, which detects pre-conception risks of cystic fibrosis, and its Warfarin Sensitivity Test, which determines an individual's ability to metabolize the oral anticoagulant warfarin, have received FDA clearance. It has also developed a Respiratory Viral Panel Test, which detects the presence of major respiratory viruses, and a Thrombosis Risk Test, which detects an individual's increased risk of blood clots. GenMark Diagnostics, Inc. is based in Pasadena, California.
What is the stock price of Genmark Diagnostics today?
The current stock price of GNMK is 24.04 null.
Does Genmark Diagnostics pay dividends?
GNMK does not pay a dividend.
How is the ChartMill rating for Genmark Diagnostics?
GNMK has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
Would investing in Genmark Diagnostics be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on GNMK.
Can you provide the market cap for Genmark Diagnostics?
Genmark Diagnostics (GNMK) has a market capitalization of 1.76B null. This makes GNMK a Small Cap stock.